Anticancer Drugs Dostarlimab Oncology Pharmacology Physiotherapy

Dostarlimab (Mechanism of Action)

In this article we will discuss Dostarlimab (Mechanism of Action)

In this article, we will discuss Dostarlimab (Mechanism of Action). So, let’s get started.

Mechanism of Action

Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors, and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.

Dostarlimab-gxly is a humanized monoclonal antibody of the IgG4 isotype that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.


Dostarlimab-gxly exposure-response relationships have not been fully characterized. Dostarlimab-gxly provides sustained target engagement as measured by PD-1 binding and stimulation of IL-2 production throughout the dosing interval at the recommended dose.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.